Alvotech (ALVO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $3.53. It has a SharesGrow Score of 59/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ALVO = $76.24 (+2059.8% from the current price, the stock appears undervalued). Analyst consensus target is ALVO = $9 (+143.6% upside).
Valuation: ALVO trades at a trailing Price-to-Earnings (P/E) of 35.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.
Financials: revenue is $586M, +155.1%/yr average growth. Net income is $28M, growing at +54.2%/yr. Net profit margin is 4.8% (thin). Gross margin is 59.8% (+37 pp trend).
Balance sheet: total debt is $1.4B with negative equity of -$284M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.89 (strong liquidity). Debt-to-assets is 97.4%. Total assets: $1.5B.
Analyst outlook: 2 / 5 analysts rate ALVO as buy (40%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 85/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 50/100 (Partial), Moat 70/100 (Pass), Future 52/100 (Partial), Income 30/100 (Fail).
